A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Scleros… (NCT00315367) | Clinical Trial Compass
CompletedPhase 4
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
United States26 participantsStarted 2004-09
Plain-language summary
The purpose of this study is to determine if medication designed to improve memory will help patients with Multiple Sclerosis (MS) who are experiencing memory problems using fMRI to track brain activity.
Who can participate
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Between 18 and 65 years of age and experiencing some forgetfulness
* Diagnosed with MS, currently taking Rebif® and experiencing mild memory problems
* Participants will have stable medication dosages 1 month prior to testing
* With no past or present neurological disorders (e.g. head trauma, seizures, encephalitis, stroke) except MS
* With no known medical illnesses (e.g. diabetes, uncontrolled hypertension, arthritis)
* With no psychiatric illness
* With no current substance abuse
* Females should not be pregnant or nursing
* With no metallic devices in the body or claustrophobia
Exclusion Criteria:
* Previous history of CNS disturbance other than MS
* Severe motor or visual impairment that might interfere with the cognitive activation tasks
* Prescribed psychoactive medications
* Memory deficits caused by other significant neurological disease or psychiatric disorder
* Active malignancy within one year of study participation
* Known human immunodeficiency virus (HIV)
* Current diagnosis of unstable glaucoma; history of myocardial infarction
* Symptomatic Coronary Artery Disease within the last 12 months or evidence of ongoing ischemia or uncontrolled atrial or ventricular arrhythmias as shown by ECG; poorly controlled or labile hypertension
* History of epilepsy or other seizure disorder within the past 12 months
* Allergy or hypersensitivity to amphetamines or other sympathomimetic amines
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Anatomic relationships during cognitive activity, and how these relationships change as a function of drug